whether they were prescribed isavuconazole using the electronic medication administration record. Between 1 January 2016 and 30 June 2017, patients were identified based on whether they had an isavuconazole serum concentration measured. Patients were included if they were on tacrolimus or sirolimus prior to initiation of isavuconazole and had at least two tacrolimus or sirolimus concentrations drawn immediately before and at least two tacrolimus or sirolimus concentrations drawn within 4 weeks after the addition of isavuconazole. Tacrolimus and sirolimus trough serum concentrations were measured up to twice weekly on specified days of the week per institutional protocol and recorded for up to 4 weeks. The first concentration drawn after the initiation of isavuconazole was labeled week 1A and the second concentration drawn within 7 days of isavuconazole was labeled week 1B. Patients were excluded if tacrolimus or sirolimus concentrations were <2 ng/mL or >15 ng/mL before, or <2 ng/mL after isavuconazole administration, or if at least Tacrolimus and sirolimus doses were adjusted based on individual clinician judgment, usually to achieve a serum concentration within the therapeutic range of 5-10 ng/mL. Isavuconazole serum concentrations, when measured, were generally measured once during the first 2 weeks of therapy. Isavuconazole doses were not adjusted based on isavuconazole levels. Microparticle enzyme immunoassay was used to measure tacrolimus serum concentrations. Liquid chromatography tandem mass spectrometry was used to measure sirolimus and isavuconazole serum concentrations.
Data collected included patient demographics (eg age, race, sex, underlying malignancy, conditioning regimen), indication, dose, route, frequency, and serum concentrations of isavuconazole, tacrolimus, and sirolimus, adverse events attributed to tacrolimus or sirolimus during the study period, other significant 
| Statistical analysis
All analyses were performed using GraphPad® Prism version 7.04 (La Jolla, CA). Data were assessed for normality using the D'Agostino and Pearson normality test. If data followed normal distribution, a paired t test was performed to compare the mean C/D to mean baseline C/D ratio at each timepoint. Otherwise, a Wilcoxon signedrank test was performed. Pearson correlation coefficient was calculated to determine the correlation between isavuconazole serum concentrations and tacrolimus and sirolimus C/D ratios. P-values of <0.05 were considered to be statistically significant, and there was no adjustment for multiple comparisons.
| RE SULTS

| Patient characteristics
A total of 396 patients were screened for inclusion. Thirty unique patients met the inclusion criteria: 22 patient cases for tacroli- All patients had tacrolimus or sirolimus serum concentrations measured at baseline, and subsequent concentrations were measured twice weekly to once every 2 weeks. Fifteen patients in the tacrolimus group and fourteen patients in the sirolimus group had isavuconazole serum concentrations measured within the first 2 weeks of therapy.
| Effect of isavuconazole on tacrolimus and sirolimus C/D ratios
To determine the magnitude of effect of isavuconazole administration on tacrolimus and sirolimus serum concentrations, we calcu- These differences in C/D ratios were not statistically significantly different from baseline.
| Correlation between isavuconazole serum concentrations and tacrolimus or sirolimus C/D ratios
To determine whether isavuconazole serum concentrations affect tacrolimus or sirolimus serum concentrations, we conducted a correlation analysis between isavuconazole serum concentrations and the tacrolimus or sirolimus C/D ratio that was measured at a similar time- 
| Safety outcomes
Over the 4-week study period, no patients in the tacrolimus group had tacrolimus serum concentrations >15 ng/mL (Figure 4 
| D ISCUSS I ON
The pharmacokinetic drug interaction between triazole antifungal agents and tacrolimus and sirolimus in alloHSCT patients is a relevant concern as these patients are at risk for invasive fungal infections and may require treatment or prophylaxis with triazole antifungal agents.
Posaconazole and voriconazole are triazole antifungal agents that may be used for the treatment or prophylaxis of invasive fungal infections.
Because they are considered to be strong inhibitors of CYP3A4, the manufacturers recommend an empirical reduction to one-third of the daily tacrolimus dose and to avoid combined therapy with sirolimus. 11, 12 However, retrospective studies have shown that combined therapy can be achieved in alloHSCT patients with an empirical sirolimus dose reduction in up to 90% when administered with voriconazole, and 30%-65% when administered with posaconazole. [13] [14] [15] Isavuconazole is a triazole antifungal agent that, unlike posaconazole and voriconazole, is approved by the Food and Drug
Administration for the treatment of invasive aspergillosis and mu- We acknowledge that our study has several limitations. Our results may not be generalizable to all populations, as our study population consisted primarily of Caucasians living in the United
States. Only 3% of our study population was African-American, and previous data have shown that African-Americans exhibit different tacrolimus pharmacokinetics compared to Caucasians. 18 Tacrolimus serum concentrations can also be affected by pharmacogenomic variation in the level of expression of CYP3A5, which we did not assess. 18, 19 Medication adherence, such as through pill counts, was not assessed for outpatients. No significant CYP3A4 drug-drug interactions were identified for any of the patients based on medication histories recorded in the medical records, however, it is possible that outpatient medication histories may have been incomplete or inaccurate. Patients at our institution are advised to avoid specific foods that are inhibitors of CYP3A4, but we were unable to assess for adherence to this recommendation.
Finally, our study included a limited number of patients, and the results should be confirmed with a larger number of patients due to intra-and interpatient variability in tacrolimus/sirolimus C/D ratios.
| CON CLUS ION
In alloHSCT patients, modest increases in tacrolimus/sirolimus C/D ratios from baseline were observed within the first 2 weeks after starting isavuconazole therapy, but no statistically significant differences were observed for the remaining timepoints. Although our results appear to indicate that alloHSCT patients on tacrolimus and/ or sirolimus who are initiated on isavuconazole can be managed with close serum concentration monitoring without empiric tacrolimus/ sirolimus dose reductions, future studies should be performed with a larger, more racially diverse set of patients, to confirm our findings.
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